Integrated PERSEVERE and endothelial biomarker risk model predicts death and persistent MODS in pediatric septic shock: a secondary analysis of a prospective observational study.

Biomarkers Endothelial dysfunction Multiple organ dysfunction syndrome Precision medicine Prognostic enrichment Sepsis Septic shock

Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
11 07 2022
Historique:
received: 08 05 2022
accepted: 21 06 2022
entrez: 11 7 2022
pubmed: 12 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Multiple organ dysfunction syndrome (MODS) is a critical driver of sepsis morbidity and mortality in children. Early identification of those at risk of death and persistent organ dysfunctions is necessary to enrich patients for future trials of sepsis therapeutics. Here, we sought to integrate endothelial and PERSEVERE biomarkers to estimate the composite risk of death or organ dysfunctions on day 7 of septic shock. We measured endothelial dysfunction markers from day 1 serum among those with existing PERSEVERE data. TreeNet® classification model was derived incorporating 22 clinical and biological variables to estimate risk. Based on relative variable importance, a simplified 6-biomarker model was developed thereafter. Among 502 patients, 49 patients died before day 7 and 124 patients had persistence of MODS on day 7 of septic shock. Area under the receiver operator characteristic curve (AUROC) for the newly derived PERSEVEREnce model to predict death or day 7 MODS was 0.93 (0.91-0.95) with a summary AUROC of 0.80 (0.76-0.84) upon tenfold cross-validation. The simplified model, based on IL-8, HSP70, ICAM-1, Angpt2/Tie2, Angpt2/Angpt1, and Thrombomodulin, performed similarly. Interaction between variables-ICAM-1 with IL-8 and Thrombomodulin with Angpt2/Angpt1-contributed to the models' predictive capabilities. Model performance varied when estimating risk of individual organ dysfunctions with AUROCS ranging from 0.91 to 0.97 and 0.68 to 0.89 in training and test sets, respectively. The newly derived PERSEVEREnce biomarker model reliably estimates risk of death or persistent organ dysfunctions on day 7 of septic shock. If validated, this tool can be used for prognostic enrichment in future pediatric trials of sepsis therapeutics.

Sections du résumé

BACKGROUND
Multiple organ dysfunction syndrome (MODS) is a critical driver of sepsis morbidity and mortality in children. Early identification of those at risk of death and persistent organ dysfunctions is necessary to enrich patients for future trials of sepsis therapeutics. Here, we sought to integrate endothelial and PERSEVERE biomarkers to estimate the composite risk of death or organ dysfunctions on day 7 of septic shock.
METHODS
We measured endothelial dysfunction markers from day 1 serum among those with existing PERSEVERE data. TreeNet® classification model was derived incorporating 22 clinical and biological variables to estimate risk. Based on relative variable importance, a simplified 6-biomarker model was developed thereafter.
RESULTS
Among 502 patients, 49 patients died before day 7 and 124 patients had persistence of MODS on day 7 of septic shock. Area under the receiver operator characteristic curve (AUROC) for the newly derived PERSEVEREnce model to predict death or day 7 MODS was 0.93 (0.91-0.95) with a summary AUROC of 0.80 (0.76-0.84) upon tenfold cross-validation. The simplified model, based on IL-8, HSP70, ICAM-1, Angpt2/Tie2, Angpt2/Angpt1, and Thrombomodulin, performed similarly. Interaction between variables-ICAM-1 with IL-8 and Thrombomodulin with Angpt2/Angpt1-contributed to the models' predictive capabilities. Model performance varied when estimating risk of individual organ dysfunctions with AUROCS ranging from 0.91 to 0.97 and 0.68 to 0.89 in training and test sets, respectively.
CONCLUSIONS
The newly derived PERSEVEREnce biomarker model reliably estimates risk of death or persistent organ dysfunctions on day 7 of septic shock. If validated, this tool can be used for prognostic enrichment in future pediatric trials of sepsis therapeutics.

Identifiants

pubmed: 35818064
doi: 10.1186/s13054-022-04070-5
pii: 10.1186/s13054-022-04070-5
pmc: PMC9275255
doi:

Substances chimiques

Biomarkers 0
Interleukin-8 0
Thrombomodulin 0
Intercellular Adhesion Molecule-1 126547-89-5

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

210

Subventions

Organisme : NIDDK NIH HHS
ID : K23DK119463
Pays : United States
Organisme : National Institute of Child Health and Human Development
ID : R01HL161362
Organisme : NIDDK NIH HHS
ID : K23 DK119463
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM126943
Pays : United States
Organisme : National Institute of Child Health and Human Development
ID : R00HD099387
Organisme : National Institute of Child Health and Human Development
ID : RL1HD107776
Organisme : NHLBI NIH HHS
ID : K23HL151897
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Am J Respir Crit Care Med. 2015 May 15;191(10):1147-57
pubmed: 25734408
Am J Respir Crit Care Med. 2020 Apr 1;201(7):848-855
pubmed: 31916857
Sci Rep. 2018 Jan 11;8(1):505
pubmed: 29323190
Crit Care Med. 2011 Nov;39(11):2511-7
pubmed: 21705885
Pediatr Crit Care Med. 2005 Jan;6(1):2-8
pubmed: 15636651
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33836597
Sci Transl Med. 2019 Nov 13;11(518):
pubmed: 31723040
JAMA. 2010 Oct 27;304(16):1787-94
pubmed: 20978258
Pediatrics. 2022 Jan 1;149(1 Suppl 1):S23-S31
pubmed: 34970683
Crit Care Med. 2020 May;48(5):725-731
pubmed: 32108704
Front Immunol. 2019 Oct 25;10:2508
pubmed: 31708927
Crit Care Med. 2016 Nov;44(11):2010-2017
pubmed: 27513537
Crit Care Med. 2020 Mar;48(3):319-328
pubmed: 32058369
Trends Mol Med. 2014 Apr;20(4):195-203
pubmed: 24581450
Am J Respir Crit Care Med. 2020 Aug 1;202(3):361-370
pubmed: 32101446
Curr Opin Pediatr. 2019 Jun;31(3):322-327
pubmed: 31090572
J Pediatr. 1997 Oct;131(4):575-81
pubmed: 9386662
Nat Rev Nephrol. 2020 Jan;16(1):20-31
pubmed: 31511662
Pediatr Crit Care Med. 2017 Aug;18(8):750-757
pubmed: 28486385
Nat Rev Nephrol. 2018 Jul;14(7):417-427
pubmed: 29691495
Pediatr Crit Care Med. 2022 Jan 1;23(1):e20-e28
pubmed: 34560770
Am J Respir Crit Care Med. 2020 Feb 1;201(3):380-384
pubmed: 31597044
Pediatr Crit Care Med. 2020 Feb;21(2):e52-e106
pubmed: 32032273
Crit Care Med. 2018 Jan;46(1):e9-e16
pubmed: 28991832
Front Pediatr. 2021 Aug 16;9:711104
pubmed: 34485201
Crit Care. 2012 Jan 16;16(1):R7
pubmed: 22248019
Pediatr Crit Care Med. 2017 Mar;18(3_suppl Suppl 1):S32-S45
pubmed: 28248832
Am J Respir Crit Care Med. 2015 Feb 1;191(3):309-15
pubmed: 25489881
Crit Care Med. 2021 Sep 1;49(9):1402-1413
pubmed: 34259449
Crit Care. 2012 Oct 01;16(5):R174
pubmed: 23025259

Auteurs

Mihir R Atreya (MR)

Division of Critical Care Medicine, MLC2005, Cincinnati Children's Hospital Medical Center, Cincinnati Children's Research Foundation, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. Mihir.Atreya@cchmc.org.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA. Mihir.Atreya@cchmc.org.

Natalie Z Cvijanovich (NZ)

UCSF Benioff Children's Hospital Oakland, Oakland, CA, 94609, USA.

Julie C Fitzgerald (JC)

Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.

Scott L Weiss (SL)

Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.

Michael T Bigham (MT)

Akron Children's Hospital, Akron, OH, 44308, USA.

Parag N Jain (PN)

Texas Children's Hospital and Baylor College of Medicine, Houston, TX, 77030, USA.

Adam J Schwarz (AJ)

Children's Hospital of Orange County, Orange, CA, 92868, USA.

Riad Lutfi (R)

Riley Hospital for Children, Indianapolis, IN, 46202, USA.

Jeffrey Nowak (J)

Children's Hospital and Clinics of Minnesota, Minneapolis, MN, 55404, USA.

Geoffrey L Allen (GL)

Children's Mercy Hospital, Kansas City, MO, 64108, USA.

Neal J Thomas (NJ)

Penn State Hershey Children's Hospital, Hershey, PA, 17033, USA.

Jocelyn R Grunwell (JR)

Children's Healthcare of Atlanta at Egleston, Atlanta, GA, 30322, USA.

Torrey Baines (T)

University of Florida Health Shands Children's Hospital, Gainesville, FL, 32610, USA.

Michael Quasney (M)

CS Mott Children's Hospital at the University of Michigan, Ann Arbor, MI, 48109, USA.

Bereketeab Haileselassie (B)

Lucile Packard Children's Hospital Stanford, Palo Alto, CA, 94304, USA.

Christopher J Lindsell (CJ)

Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37212, USA.

Matthew N Alder (MN)

Division of Critical Care Medicine, MLC2005, Cincinnati Children's Hospital Medical Center, Cincinnati Children's Research Foundation, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.

Hector R Wong (HR)

Division of Critical Care Medicine, MLC2005, Cincinnati Children's Hospital Medical Center, Cincinnati Children's Research Foundation, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH